Research Shows Medtechs Prioritizing Site Collaboration and Data Quality
Veeva Systems (NYSE:VEEV) released its 2025 MedTech Clinical Benchmark report, revealing key trends in medical technology clinical operations. The study shows that 68% of medtech teams prioritize reducing manual processes in site collaboration, while 56% focus on study quality improvement.
The report highlights significant gaps in technology adoption, with only 14% of large medtechs (>$1B revenue) and 24% of smaller companies having site collaboration tools. Additionally, 72% of organizations plan to invest in AI/ML infrastructure, while 58% will prioritize data collection and cleaning in the coming year.
Key challenges identified include on-time data entry, document exchange, and monitoring compliance, with manual processes (32%), global trial regulation compliance (18%), and inspection readiness (18%) being the top hurdles.
Veeva Systems (NYSE:VEEV) ha pubblicato il rapporto 2025 MedTech Clinical Benchmark, evidenziando le principali tendenze nelle operazioni cliniche del settore medicale. Lo studio mostra che il 68% dei team medtech dà priorità alla riduzione dei processi manuali nella collaborazione con i siti, mentre il 56% punta al miglioramento della qualità degli studi.
Il rapporto sottolinea lacune significative nell'adozione tecnologica: solo il 14% delle grandi medtech (ricavi >$1B) e il 24% delle aziende più piccole dispongono di strumenti per la collaborazione con i siti. Inoltre, il 72% delle organizzazioni prevede investimenti in infrastrutture AI/ML, mentre il 58% darà priorità alla raccolta e pulizia dei dati nel prossimo anno.
Le principali sfide identificate includono l'inserimento puntuale dei dati, lo scambio di documenti e la conformità al monitoraggio, con processi manuali (32%), conformità alla regolamentazione globale dei trial (18%) e prontezza alle ispezioni (18%) come ostacoli principali.
Veeva Systems (NYSE:VEEV) publicó su informe 2025 MedTech Clinical Benchmark, que revela las tendencias clave en las operaciones clínicas de tecnología médica. El estudio indica que el 68% de los equipos medtech prioriza reducir los procesos manuales en la colaboración con los sitios, mientras que el 56% se centra en mejorar la calidad del estudio.
El informe destaca brechas importantes en la adopción tecnológica: solo el 14% de las grandes medtech (ingresos >$1B) y el 24% de las empresas más pequeñas cuentan con herramientas de colaboración con sitios. Además, el 72% de las organizaciones planea invertir en infraestructura de IA/ML, y el 58% dará prioridad a la recopilación y limpieza de datos en el próximo año.
Los desafíos principales incluyen la entrada de datos a tiempo, el intercambio de documentos y el cumplimiento del monitoreo, siendo los procesos manuales (32%), la conformidad con la regulación global de ensayos (18%) y la preparación para inspecciones (18%) los mayores obstáculos.
Veeva Systems (NYSE:VEEV)는 2025 MedTech Clinical Benchmark 보고서를 발표하여 의료기술(메드텍) 임상 운영의 주요 동향을 공개했습니다. 연구에 따르면 메드텍 팀의 68%가 사이트 협업에서 수작업 절차 축소를 우선시하며, 56%는 연구 품질 향상에 중점을 둡니다.
보고서는 기술 도입의 큰 격차를 지적합니다: 매출 >$1B의 대형 메드텍 중 14%만, 더 작은 기업들 중 24%만이 사이트 협업 도구를 보유하고 있습니다. 또한 72%의 조직이 AI/ML 인프라에 투자할 계획이며, 58%는 향후 1년간 데이터 수집 및 정리에 우선순위를 둘 것이라고 응답했습니다.
주요 과제는 적시 데이터 입력, 문서 교환 및 모니터링 규정 준수로, 수작업 프로세스(32%), 글로벌 시험 규제 준수(18%), 검사 대비(18%)가 주요 장애물로 꼽혔습니다.
Veeva Systems (NYSE:VEEV) a publié son rapport 2025 MedTech Clinical Benchmark, révélant les tendances clés des opérations cliniques en technologie médicale. L'étude montre que 68% des équipes medtech donnent la priorité à la réduction des processus manuels dans la collaboration avec les sites, tandis que 56% se concentrent sur l'amélioration de la qualité des études.
Le rapport souligne des lacunes importantes dans l'adoption technologique : seulement 14% des grandes medtech (chiffre d'affaires >$1B) et 24% des entreprises plus petites disposent d'outils de collaboration avec les sites. De plus, 72% des organisations prévoient d'investir dans des infrastructures IA/ML, tandis que 58% donneront la priorité à la collecte et au nettoyage des données au cours de l'année à venir.
Les principaux défis identifiés incluent la saisie des données en temps voulu, l'échange de documents et la conformité du monitoring, les processus manuels (32%), le respect des réglementations mondiales sur les essais (18%) et la préparation aux inspections (18%) constituant les principaux obstacles.
Veeva Systems (NYSE:VEEV) hat seinen 2025 MedTech Clinical Benchmark Report veröffentlicht und wichtige Trends in den klinischen Abläufen der Medizintechnik aufgezeigt. Die Studie zeigt, dass 68% der MedTech-Teams die Reduzierung manueller Prozesse bei der Zusammenarbeit mit Studienzentren priorisieren, während 56% die Verbesserung der Studienqualität in den Fokus stellen.
Der Bericht hebt erhebliche Lücken bei der Technologieeinführung hervor: Nur 14% der großen MedTech-Unternehmen (Umsatz >$1B) und 24% der kleineren Firmen verfügen über Tools für die Zusammenarbeit mit Studienzentren. Zudem planen 72% der Organisationen Investitionen in AI/ML-Infrastruktur, während 58% im kommenden Jahr Datenerfassung und -bereinigung priorisieren werden.
Als zentrale Herausforderungen werden fristgerechte Dateneingabe, Dokumentenaustausch und Überwachungs-Compliance genannt; manuelle Prozesse (32%), Einhaltung globaler Prüfungsvorschriften (18%) und Inspektionsbereitschaft (18%) sind die größten Hürden.
- 72% of medtech organizations are planning to invest in AI/ML infrastructure
- 58% of medtechs prioritizing data collection and cleaning optimization
- Companies actively working to modernize clinical operations and improve efficiency
- Only 14% of large medtechs have site collaboration tools implemented
- 32% still rely heavily on manual processes, increasing operational risks
- Significant challenges with data quality and document exchange persist
Insights
Veeva's industry report identifies significant market opportunity for its clinical trial collaboration products as medtechs struggle with manual processes.
Veeva Systems' latest MedTech Clinical Benchmark reveals a significant market opportunity for the company's clinical operations platform. The research identifies a critical gap: while
This disconnect creates a compelling sales opportunity for Veeva's clinical products. The research strategically highlights pain points that Veeva's solutions directly address: on-time data entry, document exchange, and compliance monitoring. By quantifying that
For investors, this research serves a dual purpose: it demonstrates Veeva's deep industry understanding and subtly markets its solutions by highlighting gaps its products can fill. The report effectively frames industry challenges around data quality, regulatory compliance, and process optimization—precisely where Veeva's value proposition lies. This represents classic market development strategy, using proprietary research to validate product-market fit and create urgency around adoption.
Nearly
Respondents identified on-time data entry and data quality, exchange of documents and data, and monitoring and compliance as the biggest challenges for site management. However, only
Additional insights about today's medtech clinical landscape from the benchmark report include:
- Manual processes increase risk. Reliance on manual processes (
32% ), complying with global trial regulation (18% ), and inspection readiness (18% ) were cited most often as the top hurdle in medtech clinical affairs. These high-risk areas can increase operational costs and cause significant trial delays. - Process optimization efforts are underway. To maintain the integrity of clinical trials,
58% of medtechs plan to prioritize data collection and cleaning in the next year. By optimizing the data collection process, teams can spend less time on data reconciliation and focus on high-value trial activities. - AI and ML initiatives are in early stages. Nearly three out of four medtech organizations (
72% ) are planning to invest in infrastructure for AI and ML solutions, working to harmonize existing systems and standardize data to make it AI-ready.
"The medtech industry is driving initiatives to advance clinical processes, site collaboration, and data quality amidst economic pressures and new regulations," said Kevin Liang, vice president, clinical strategy, Veeva MedTech. "The report shows medtech companies are investing their efforts to ensure data integrity, improve operational efficiency, and drive connected processes across stakeholders to bring new technologies to patients faster."
The 2025 Veeva MedTech Clinical Benchmark surveyed more than 100 clinical professionals at medical device and diagnostics companies. The report examines the current state of medtech clinical trials and how teams are working to modernize their operations. To learn more, read the full report.
About Veeva MedTech
Veeva MedTech helps medical device and diagnostics companies streamline the complete product development and commercialization lifecycles to deliver products to patients with greater speed and efficiency. Veeva MedTech's offering includes applications that advance clinical, regulatory, quality, commercial, and medical operations. For more information, visit veeva.com/medtech.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Deivis Mercado
Veeva Systems
deivis.mercado@veeva.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/research-shows-medtechs-prioritizing-site-collaboration-and-data-quality-302527421.html
SOURCE Veeva Systems
FAQ
What are the key findings of Veeva's 2025 MedTech Clinical Benchmark report?
What percentage of medtech companies currently use site collaboration tools in 2025?
What are the main challenges in medtech clinical trials according to the Veeva report?
How many medtech organizations are planning to invest in AI and ML solutions?
What percentage of medtechs are prioritizing data collection and cleaning in 2025?
